Linus Jönsson

About me
Publications
Grants
CV
Public outreach and news

About me

Linus Jönsson was born in Lund in 1975. He graduated with a medical degree from Uppsala University in 2000 and a Master’s in business and economics from the Stockholm School of Economics in 2001.

Linus Jönsson earned his PhD from Karolinska Institutet in 2003, became a registered doctor in 2004 and docent in 2019. He has previously worked with commissioned health economics research and in the drugs industry.

Linus Jönsson was appointed Professor of Health Economics at Karolinska Institutet on 24 January 2023.

Articles

Article: JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES. 2024;79(4):glae010

Associations of Orthostatic Hypotension and Frailty With Dementia and Mortality in Older Adults: A Population-Based Cohort Study

Xia X; Jonsson L; Tazzeo C; Qiu C; Rizzuto D; Laukka EJ; Grande G; Fratiglioni L; Vetrano DL
Article: JOURNAL OF HEADACHE AND PAIN. 2024;25(1):45

Structural equation modeling for identifying the drivers of health-related quality of life improvement experienced by patients with migraine receiving eptinezumab

Jonsson L; Awad SF; Regnier SA; Talon B; Kymes S; Lee XY; Goadsby PJ
Article: ALZHEIMERS RESEARCH & THERAPY. 2024;16(1):48

Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer's disease

Jonsson L; Ivkovic M; Atri A; Handels R; Gustavsson A; Hahn-Pedersen JH; Leon T; Lilja M; Gundgaard J; Raket LL
Article: ALZHEIMERS & DEMENTIA. 2024;20(2):809-818

Predicting sojourn times across dementia disease stages, institutionalization, and mortality

Tate AE; Bouteloup V; van Maurik IS; Jean D; Mank A; Speh A; Boilet V; van Harten A; Eriksdotter M; Wimo A; Dufouil C; van der Flier WM; Joensson L
Article: JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE. 2024;11(1):155-161

Estimates of Current Capacity for Diagnosing Alzheimer's Disease in Sweden and the Need to Expand Specialist Numbers

Mattke S; Gustavsson A; Jacobs L; Kern S; Palmqvist S; Eriksdotter M; Skoog I; Winblad B; Wimo A; Jonsson L
Article: JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE. 2024;11(4):928-942

Optimising Alzheimer's Disease Diagnosis and Treatment: Assessing Cost-Utility of Integrating Blood Biomarkers in Clinical Practice for Disease-Modifying Treatment

Aye S; Handels R; Winblad B; Jonsson L
Article: JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE. 2024;11(2):329-338

Validation, Deployment, and Real-World Implementation of a Modular Toolbox for Alzheimer's Disease Detection and Dementia Risk Reduction: The AD-RIDDLE Project

Malzbender K; Barbarino P; Ferrell PB; Bradshaw A; Brookes AJ; Diaz C; van der Flier WM; Georges J; Hansson O; Hartmanis M; Jonsson L; Krishnan R; MacLeod T; Mangialasche F; Mecocci P; Minguillon C; Middleton L; Pla S; Sardi SP; Scholl M; Suarez-Calvet M; Weidner W; Visser PJ; Zetterberg H; Bose N; Solomon A; Kivipelto M
Journal article: ALZHEIMERS & DEMENTIA. 2023;19(S21)

Estimating Treatment Effects of Disease‐modifying Drugs: Traditional Methods vs. Accelerated Failure Time Models and Progression Analysis

Atri A; Ivkovic M; Jönsson L; Gustavsson A; Léon T; Hahn‐Pedersen JH; Handels R; Raket LL
Journal article: ALZHEIMERS & DEMENTIA. 2023;19(S23)

The potential cost‐effectiveness of roflumilast drug treatment in mild cognitive impairment

Handels R; Grimm S; Blokland A; Possemis N; Ramakers IHGB; Sambeth A; Verhey FRJ; Vos SJB; Joore M; Prickaerts J; Jönsson L
Journal article: ALZHEIMERS & DEMENTIA. 2023;19(S21)

Incorporating clinical trial outcomes in health economic evaluations of disease‐modifying therapies for AD

Jönsson L; Gustavsson A; Handels R
Journal article: VALUE IN HEALTH. 2023;26(12):s411

MSR98 Generate Synthetic Data in R for a Hypothetical Alzheimer's Disease Trial

Handels R; Jönsson L; Raket LL
Journal article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2023;39(S1):s42

OP142 Progression Analysis Versus Traditional Methods To Quantify Slowing Of Disease Progression In Alzheimer’s Disease

Jönsson L; Ivkovic M; Handels R; Gustavsson A; León T; Hahn-Pedersen JH; Raket LL
Journal article: ALZHEIMERS & DEMENTIA. 2023;19(S19)

Health‐related quality of life in full spectrum of Alzheimer’s disease: a longitudinal analysis

Aye S; Bouteloup V; Jean D; Jönsson L
Journal article: ALZHEIMERS & DEMENTIA. 2023;19(S22)

Associations of orthostatic hypotension and frailty with dementia and mortality in older adults: a cohort study

Xia X; Tazzeo C; Jönsson L; Qiu C; Rizzuto D; Laukka EJ; Okoye C; Grande G; Fratiglioni L; Vetrano DL
Journal article: ALZHEIMERS & DEMENTIA. 2023;19(S21)

Cost‐effectiveness of amyloid‐targeting therapies: modelling based on 5724 biomarker positive AD patients in the Swedish Registry of Cognitive Disorders

Jönsson L; Skillback T; Kern S; Winblad B; Blennow K; Eriksdotter M; Zetterberg H; Wimo A
Journal article: ALZHEIMERS & DEMENTIA. 2023;19(S22)

Predicting Sojourn Times across Dementia Disease Stages, Institutionalization, and Mortality

Tate A; Bouteloup V; van Maurik IS; Mank A; Speh A; Eriksdotter M; Wimo A; Dufouil C; van der Flier WM; Jönsson L
Journal article: VALUE IN HEALTH. 2023;26(12):s419

MSR136 IPECAD Modeling Workshop 2023 Cross Comparison Challenge on Cost-Effectiveness Models in Alzheimer's Disease and Related Dementias

Handels R; Herring W; Kamgar F; Gustavsson A; Skoldunger A; Wimo A; Tate A; Winblad B; Stellick CB; Bruck C; Green C; de Kok I; Hlavka J; Mar J; Urbich M; Soto-Gordoa M; Pemberton-Ross P; Aye S; Jönsson L; Participants W
Article: ALZHEIMERS RESEARCH & THERAPY. 2023;15(1):200

Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis

Aye S; Bouteloup V; Tate A; Wimo A; Handels R; Jean D; Winblad B; Joensson L
Article: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2023;23(7):797-803

Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trial

Jonsson L; Regnier SA; Kymes S; Awad SF; Talon B; Lee XY; Goadsby PJ
Article: ALZHEIMERS & DEMENTIA. 2023;19(8):3458-3471

The value of maintaining cognition in patients with mild cognitive impairment: The innovation headroom and potential cost-effectiveness of roflumilast

Handels R; Grimm S; Blokland A; Possemis N; Ramakers I; Sambeth A; Verhey F; Vos S; Joore M; Prickaerts J; Jonsson L
Article: ALZHEIMERS & DEMENTIA. 2023;19(7):3244-3249

A glycan epitope correlates with tau in serum and predicts progression to Alzheimer's disease in combination with APOE4 allele status

Zhou RZ; Vetrano DL; Grande G; Duell F; Jonsson L; Laukka EJ; Fredolini C; Winblad B; Tjernberg L; Schedin-Weiss S
Article: ALZHEIMERS & DEMENTIA. 2023;19(7):2865-2873

The worldwide costs of dementia in 2019

Wimo A; Seeher K; Cataldi R; Cyhlarova E; Dielemann JL; Frisell O; Guerchet M; Jonsson L; Malaha AK; Nichols E; Pedroza P; Prince M; Knapp M; Dua T
Article: CLINICAL DRUG INVESTIGATION. 2023;43(7):529-540

Estimating the Product Lifecycle Value of Trastuzumab Based on Registry Data in Sweden

Justo N; Wilking N; Jonsson L
Journal article: ALZHEIMERS & DEMENTIA. 2023;19(S8)

Health‐economic innovation headroom in mild cognitive impairment due to Alzheimer’s diseas

Handels R; Jönsson L
Article: LANCET REGIONAL HEALTH-EUROPE. 2023;29:100657

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint

Joensson L; Wimo A; Handels R; Johansson G; Boada M; Engelborghs S; Froelich L; Jessen F; Kehoe PG; Kramberger M; de Mendon A; Ousset PJ; Scarmeas N; Visser PJ; Waldemar G; Winblad B
Article: ALZHEIMERS & DEMENTIA. 2023;19(5):1800-1820

Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge

Handels RLH; Green C; Gustavsson A; Herring WL; Winblad B; Wimo A; Skoldunger A; Karlsson A; Anderson R; Belger M; Bruck C; Espinosa R; Hlavka JP; Jutkowitz E; Lin P-J; Mendez ML; Mar J; Shewmaker P; Spackman E; Tafazzoli A; Tysinger B; Jonsson L
Article: ALZHEIMERS & DEMENTIA. 2023;19(3):999-1008

Dementia prevention: The potential long-term cost-effectiveness of the FINGER prevention program

Wimo A; Handels R; Antikainen R; Eriksdotter M; Jonsson L; Knapp M; Kulmala J; Laatikainen T; Lehtisalo J; Peltonen M; Skoldunger A; Soininen H; Solomon A; Strandberg T; Tuomilehto J; Ngandu T; Kivipelto M
Journal article: US NEUROLOGY. 2023;19(1):14

Lecanemab: The Price of a Breakthrough

Wimo A; Jönsson L; Johansson G; Winblad B
Article: ALZHEIMER'S AND DEMENTIA: DIAGNOSIS, ASSESSMENT AND DISEASE MONITORING. 2023;15(1):e12422

Effect of mortality in cost-effectiveness modeling of disease-modifying treatment for Alzheimer's disease

Aye S; Jonsson L; Gustavsson A; Tate A; Ptacek SG; Eriksdotter M
Article: FRONTIERS IN NEUROLOGY. 2023;14:1175922

Precision medicine in neurodegeneration: the IHI-PROMINENT project

Tate A; Suarez-Calvet M; Ekelund M; Eriksson S; Eriksdotter MM; Van der Flier W; Georges J; Kivipelto MG; Kramberger M; Lindgren P; Lopez JDG; Lotjonen J; Persson S; Pla S; Solomon A; Thurfjell L; Wimo A; Winblad B; Jonsson L
Journal article: VALUE IN HEALTH. 2022;25(12):s31-s32

CO72 Predicting Sojourn Times by Dementia Stages: Evidence From 76,747 Patients in the Swedish National Registry for Cognitive Disorders (SVEDEM)

Tate A; Jönsson L
Journal article: ALZHEIMERS & DEMENTIA. 2022;18(S8)

A longitudinal study on quality of life along the spectrum of Alzheimer’s disease

Mank A; Rijnhart JJM; van Maurik IS; Jönsson L; Handels R; Bakker ED; Teunissen CE; van Berckel BN; van Harten AC; Berkhof J; van der Flier WM
Journal article: ALZHEIMERS & DEMENTIA. 2022;18(S11)

Costs of dementia in Europe: a systematic literature review and meta‐analysis

Jönsson L; Frisell O; Wimo A
Journal article: VALUE IN HEALTH. 2022;25(12):s483

SA3 Effect of Mortality on Cost-Effectiveness Modeling of Disease-Modifying Treatment for Alzheimer's Disease

Aye S; Jönsson L
Journal article: VALUE IN HEALTH. 2022;25(12):s436

PCR237 Effect of Eptinezumab on Utility Scores in Patients With Migraine: Results From the Deliver Study

Jönsson L; Regnier; Kymes S; Talon B; Awad S; Lee X; Goadsby P
Journal article: VALUE IN HEALTH. 2022;25(12):s390

PCR4 Disease-Specific Quality-of-Life Measures Mapped to the EQ-5D in a Chronic Disorder With Recurrent Attacks: Analysis of the Deliver Trial in Patients With Migraine

Jönsson L; Regnier; Kymes S; Awad S; Talon B; Lee X; Goadsby P
Article: ALZHEIMERS RESEARCH & THERAPY. 2022;14(1):132

A longitudinal study on quality of life along the spectrum of Alzheimer's disease

Mank A; Rijnhart JJM; van Maurik IS; Jonsson L; Handels R; Bakker ED; Teunissen CE; van Berckel BNM; van Harten AC; Berkhof J; van der Flier WM
Article: MOVEMENT DISORDERS. 2022;37(7):1425-1431

Sensitivity to Change and Patient-Centricity of the Unified Multiple System Atrophy Rating Scale Items: A Data-Driven Analysis

Krismer F; Seppi K; Jonsson L; Astrom DO; Berger A-K; Simonsen J; Gordon MF; Wenning GK; Poewe W
Article: ALZHEIMER'S AND DEMENTIA: TRANSLATIONAL RESEARCH AND CLINICAL INTERVENTIONS. 2022;8(1):e12360

Health economic modeling for Alzheimer's disease: Expert perspectives

Landeiro F; Morton J; Gustavsson A; Potashman M; Lecomte P; Belger M; Thompson R; Roncancio-Diaz E; Jhuti G; Butler C; Jonsson L; Handels R; Gray AM
Article: JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE. 2022;9(1):12-21

Blood Derived Amyloid Biomarkers for Alzheimer's Disease Prevention

Udeh-Momoh C; Zheng B; Sandebring-Matton A; Novak G; Kivipelto M; Jonsson L; Middleton L
Article: BMC PSYCHIATRY. 2021;21(1):634

Predicting time to relapse in patients with schizophrenia according to patients' relapse history: a historical cohort study using real-world data in Sweden

Jorgensen KT; Bog M; Kabra M; Simonsen J; Adair M; Jonsson L
Article: NEUROLOGY. 2021;96(17):e2220-e2230

Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality

Xu H; Garcia-Ptacek S; Jonsson L; Wimo A; Nordstrom P; Eriksdotter M
Article: ALZHEIMER'S AND DEMENTIA: TRANSLATIONAL RESEARCH AND CLINICAL INTERVENTIONS. 2021;7(1):e12189

Identifying relevant outcomes in the progression of Alzheimer's disease; what do patients and care partners want to know about prognosis?

Mank A; van Maurik IS; Bakker ED; van de Glind EMM; Jonsson L; Kramberger MG; Novak P; Diaz A; Gove D; Scheltens P; van der Flier WM; Visser LNC
Journal article: ALZHEIMERS & DEMENTIA. 2020;16(S6)

Long‐term treatment with cholinesterase inhibitors in Alzheimer's disease is associated with modest but persisting benefits on cognition and reduced mortality

Eriksdotter M; Xu H; Jönsson L; Wimo A; Nordström P; Garcia‐Ptacek S
Journal article: ALZHEIMERS & DEMENTIA. 2020;16(S7)

Informal care time in dementia by cognitive, functional and behavioral disease severity from eight longitudinal cohorts across multiple countries

Handels R; Jönsson L; Green C; Winblad B; Wimo A; Actifcare ID
Article: TRANSLATIONAL PSYCHIATRY. 2020;10(1):364

Transdiagnostic individualized clinically-based risk calculator for the automatic detection of individuals at-risk and the prediction of psychosis: external replication in 2,430,333 US patients

Oliver D; Wong CMJ; Bog M; Jonsson L; Kinon BJ; Wehnert A; Jorgensen KT; Irving J; Stahl D; McGuire P; Raket LL; Fusar-Poli P
Article: THE LANCET. HEALTHY LONGEVITY. 2020;1(1):e2-e3

The art of simulation

Wimo A; Handels R; Jonsson L
Article: LANCET DIGITAL HEALTH. 2020;2(5):e229-e239

Dynamic ElecTronic hEalth reCord deTection (DETECT) of individuals at risk of a first episode of psychosis: a case-control development and validation study

Raket LL; Jaskolowski J; Kinon BJ; Brasen JC; Jonsson L; Wehnert A; Fusar-Poli P
Article: ALZHEIMERS & DEMENTIA. 2020;16(5):789-796

Controlling for selective dropout in longitudinal dementia data: Application to the SveDem registry

Handels R; Jonsson L; Garcia-Ptacek S; Eriksdotter M; Wimo A
Article: JOURNAL OF ALZHEIMERS DISEASE. 2020;73(3):967-979

Costs of Inpatient Rehabilitation for Ischemic Stroke in Patients with Dementia: A Cohort Swedish Register-Based Study

Minh TH; Kareholt I; von Euler M; Jonsson L; von Koch L; Eriksdotter M; Garcia-Ptacek S
Article: ALZHEIMERS & DEMENTIA. 2019;15(10):1309-1321

Assessing cost-effectiveness of early intervention in Alzheimer's disease: An open-source modeling framework

Green C; Handels R; Gustavsson A; Wimo A; Winblad B; Skoldunger A; Jonsson L
Article: INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH. 2019;28(3):e1778

Identifying and characterizing treatment-resistant schizophrenia in observational database studies

Jonsson L; Simonsen J; Brain C; Kymes S; Watson L
Journal article: ALZHEIMERS & DEMENTIA. 2019;15(7S_Part_4):p245

P1‐033: ASSOCIATION WITH REDUCED MORTALITY USING CHOLINESTERASE INHIBITORS IN PATIENTS WITH DEMENTIA: DATA FROM SVEDEM, THE SWEDISH DEMENTIA REGISTRY

Xu H; Garcia-Ptacek S; Jonsson L; Wimo A; Nordström P; Eriksdotter M
Journal article: ALZHEIMERS & DEMENTIA. 2019;15(7S_Part_31):p1636

O5‐08‐04: A NEW OPEN‐SOURCE MODELING FRAMEWORK TO ASSESS COST EFFECTIVENESS OF EARLY INTERVENTION IN ALZHEIMER'S DISEASE

Green C; Handels R; Gustavsson A; Wimo A; Skoldunger A; Winblad B; Jonsson L
Journal article: ALZHEIMERS & DEMENTIA. 2019;15(7S_Part_31):p1637

O5‐08‐05: STRUCTURAL UNCERTAINTY AND CROSS‐VALIDATION OF DECISION MODELS IN THE AD SETTING: ANSWERING QUESTIONS FROM POLICY MAKERS ON THE RELIABILITY OF HEALTH‐ECONOMIC MODELS

Handels R; Jönsson L; Green C; Eriksdotter M; Qiu C; Winblad B; Wimo A
Article: MULTIPLE SCLEROSIS JOURNAL. 2019;25(5):740-749

The effect of self-assessed fatigue and subjective cognitive impairment on work capacity: The case of multiple sclerosis

Kobelt G; Langdon D; Jonsson L
Article: MULTIPLE SCLEROSIS INTERNATIONAL. 2019;2019:7290285-8

Real-Life Outcome in Multiple Sclerosis in the Czech Republic

Kobelt G; Joensson L; Pavelcova M; Havrdova EK
Article: IEEE REVIEWS IN BIOMEDICAL ENGINEERING. 2019;12:319-332

Technology-Enabled Assessment of Functional Health

Cook DJ; Schmitter-Edgecombe M; Jonsson L; Morant AV
Article: BMC NEUROLOGY. 2017;17(1):213

Inventory of real world data sources in Parkinson's disease

Tanguy A; Joensson L; Ishihara L
Article: ALZHEIMERS & DEMENTIA. 2017;13(1):1-7

The worldwide costs of dementia 2015 and comparisons with 2010

Wimo A; Guerchet M; Ali G-C; Wu Y-T; Prina AM; Winblad B; Jonsson L; Liu Z; Prince M
Article: ALZHEIMERS RESEARCH & THERAPY. 2016;8(1):59

The societal costs of dementia in Sweden 2012-relevance and methodological challenges in valuing informal care

Wimo A; Jonsson L; Fratiglioni L; Sandman PO; Gustavsson A; Skoldunger A; Johansson L
Article: EUROPEAN JOURNAL OF CANCER CARE. 2016;25(3):466-477

Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherpy. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study

Jonsson L; Justo N; Musayev A; Krishna A; Burke T; Pellissier J; Judson I; Staddon A; Blay JY
Article: LANCET NEUROLOGY. 2016;15(5):455-532

Defeating Alzheimer's disease and other dementias: a priority for European science and society

Winblad B; Amouyel P; Andrieu S; Ballard C; Brayne C; Brodaty H; Cedazo-Minguez A; Dubois B; Edvardsson D; Feldman H; Fratiglioni L; Frisoni GB; Gauthier S; Georges J; Graff C; Iqbal K; Jessen F; Johansson G; Jonsson L; Kivipelto M; Knapp M; Mangialasche F; Melis R; Nordberg A; Rikkert MO; Qiu C; Sakmar TP; Scheltens P; Schneider LS; Sperling R; Tjernberg LO; Waldemar G; Wimo A; Zetterberg H
Article: VALUE IN HEALTH. 2014;17(6):707-713

Analyzing Overall Survival in Randomized Controlled Trials with Crossover and Implications for Economic Evaluation

Jonsson L; Sandin R; Ekman M; Ramsberg J; Charbonneau C; Huang X; Jonsson B; Weinstein MC; Drummond M
Article: JOURNAL OF INTERNAL MEDICINE. 2014;275(3):304-316

Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria

Wimo A; Ballard C; Brayne C; Gauthier S; Handels R; Jones RW; Jonsson L; Khachaturian AS; Kramberger M
Article: CANCER MANAGEMENT AND RESEARCH. 2014;6:365-371

Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study

Tang Y; Bycott P; Akerborg O; Jonsson L; Negrier S; Chen C
Journal article: ALZHEIMERS & DEMENTIA. 2013;9(4S_Part_11):p467

P2–298: Assessing the economic value of potential disease‐modifying agents in Alzheimer's disease using simulation

Getsios D; Guo S; Revankar N; Jonsson L; Neumann P; Thompson G; Bobula J; Lacey L; Gaudig M
Article: ALZHEIMERS & DEMENTIA. 2013;9(4):429-435.e17

Application of Resource Utilization in Dementia (RUD) instrument in a global setting

Wimo A; Gustavsson A; Jonsson L; Winblad B; Hsu M-A; Gannon B
Article: LUPUS. 2013;22(8):793-801

Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports

Bexelius C; Wachtmeister K; Skare P; Jonsson L; van Vollenhoven R
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2013;72(Suppl 3):a477-A478

FRI0306 Costs and working capacity among patients with systemic lupus erythematosus (SLE) in working-age (18-64 years)

Bexelius C; Wachtmeister K; Skare P; Jönsson L; van Vollenhoven RF
Article: BMC HEALTH SERVICES RESEARCH. 2013;13:173

Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece

Maniadakis N; Kourlaba G; Mougiakos T; Chatzimanolis I; Jonsson L
Article: INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2013;28(5):454-462

Costs explained by function rather than diagnosis-results from the SNAC Nordanstig elderly cohort in Sweden

Lindholm C; Gustavsson A; Jonsson L; Wimo A
Article: ARCHIVES OF OSTEOPOROSIS. 2013;8(1-2):144

SCOPE: a scorecard for osteoporosis in Europe

Kanis JA; Borgstrom F; Compston J; Dreinhoefer K; Nolte E; Jonsson L; Lems WF; McCloskey EV; Rizzoli R; Stenmark J
Article: ALZHEIMERS & DEMENTIA. 2013;9(1):1-11.e3

The worldwide economic impact of dementia 2010

Wimo A; Jonsson L; Bond J; Prince M; Winblad B
Journal article: VALUE IN HEALTH. 2012;15(7):a422

PCN75 Survival and Costs in Metastatic Renal Cell Carcinoma: A Comparison of mRCC Treatment Pre- and Post Tyrosine Kinase Inhibitor (TKI) Introduction Using Retrospective Registry Data

Jönsson L; Sandin R; Lindgren P; Kowalski J; Wahlgren T; Harmenberg U; Sandström P; Ljungberg B; Jakobsson M
Journal article: VALUE IN HEALTH. 2012;15(7):a464

PRM24 Methods for Analysis of Censored Cost Data

Jönsson L
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2012;13(5):561-568

Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort

Gustavsson A; Jonsson L; Parmler J; Andreasen N; Wattmo C; Wallin AK; Minthon L
Article: ANNALS OF ONCOLOGY. 2012;23(10):2763-2770

Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study

Leahy M; Garcia del Muro X; Reichardt P; Judson I; Staddon A; Verweij J; Baffoe-Bonnie A; Jonsson L; Musayev A; Justo N; Burke T; Blay JY
Article: EUROPEAN JOURNAL OF NEUROLOGY. 2012;19(1):155-162

The economic cost of brain disorders in Europe

Olesen J; Gustavsson A; Svensson M; Wittchen H-U; Jonsson B
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2011;21(10):718-779

Cost of disorders of the brain in Europe 2010

Gustavsson A; Svensson M; Jacobi F; Allgulander C; Alonso J; Beghi E; Dodel R; Ekman M; Faravelli C; Fratiglioni L; Gannon B; Jones DH; Jennum P; Jordanova A; Jonsson L; Karampampa K; Knapp M; Kobelt G; Kurth T; Lieb R; Linde M; Ljungcrantz C; Maercker A; Melin B; Moscarelli M; Musayev A; Norwood F; Preisig M; Pugliatti M; Rehm J; Salvador-Carulla L; Schlehofer B; Simon R; Steinhausen H-C; Stovner LJ; Vallat J-M; Van den Bergh P; van Os J; Vos P; Xu W; Wittchen H-U; Jonsson B; Olesen J
Article: INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2011;26(8):825-832

The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project

Wimo A; Jonsson L; Gustavsson A; McDaid D; Ersek K; Georges J; Gulacsi L; Karpati K; Kenigsberg P; Valtonen H
Article: ALZHEIMERS & DEMENTIA. 2011;7(4):466-473

Costs of care in a mild-to-moderate Alzheimer clinical trial sample: Key resources and their determinants

Gustavsson A; Cattelin F; Jonsson L
Article: ALZHEIMERS & DEMENTIA. 2011;7(3):318-327

Predictors of costs of care in Alzheimer's disease: A multinational sample of 1222 patients

Gustavsson A; Brinck P; Bergvall N; Kolasa K; Wimo A; Winblad B; Jonsson L
Article: INTERNATIONAL PSYCHOGERIATRICS. 2011;23(1):73-85

Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease

Bergvall N; Brinck P; Eek D; Gustavsson A; Wimo A; Winblad B; Jonsson L
Article: NEUROLOGY. 2010;75(14):1256-1262

Assessment of potential measures in models of progression in Alzheimer disease

McLaughlin T; Buxton M; Mittendorf T; Redekop W; Mucha L; Darba J; Jonsson L; Lacey L; Leibman C
Article: JOURNAL OF NUTRITION HEALTH & AGING. 2010;14(8):685-690

The resource utilization in dementia (RUD) instrument is valid for assessing informal care time in community-living patients with dementia

Wimo A; Jonsson L; Zbrozek A
Article: JOURNAL OF NUTRITION HEALTH & AGING. 2010;14(8):648-654

Differences in resource use and costs of dementia care between European countries: Baseline data from the ictus study

Gustavsson A; Jonsson L; Rapp T; Reynish E; Ousset PJ; Andrieu S; Cantet C; Winblad B; Vellas B; Wimo A
Article: JOURNAL OF NUTRITION HEALTH & AGING. 2010;14(8):633-639

Costs of dementia in Hungary

Ersek K; Kovacs T; Wimo A; Karpati K; Brodszky V; Pentek M; Joensson L; Gustavsson A; Mcdaid D; Kenigsberg PA; Valtonen H; Gulacsi L
Journal article: ALZHEIMERS & DEMENTIA. 2010;6(4S_Part_12):s373

P2‐202: Dementia work‐up is more costly in men than in women

Religa D; Spangberg K; Wimo A; Jonsson L; Edlund A-K; Winblad B; Eriksdotter-Jonhagen M
Article: INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2010;25(6):622-632

Willingness-to-pay for reductions in care need: estimating the value of informal care in Alzheimer's disease

Gustavsson A; Jonsson L; McShane R; Boada M; Wimo A; Zbrozek AS
Article: CURRENT ALZHEIMER RESEARCH. 2010;7(4):358-367

Cross Sectional Observational Study on the Societal Costs of Alzheimer's Disease

Mesterton J; Wimo A; By A; Langworth S; Winblad B; Jonsson L
Article: INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2010;25(5):476-482

The cost of diagnosing dementia in a community setting

Jedenius E; Wimo A; Stromqvist J; Jonsson L; Andreasen N
Article: JOURNAL OF NUTRITION HEALTH & AGING. 2010;14(5):358-360

IPECAD5-Fifth International Pharmaco-Economic Conference on Alzheimer's Disease

Gustavsson A; Jonsson L; Fillit H; Johansson G; Wimo A; Winblad B
Article: ALZHEIMERS & DEMENTIA. 2010;6(2):98-103

The worldwide societal costs of dementia: Estimates for 2009

Wimo A; Winblad B; Jonsson L
Article: APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 2010;8(5):317-325

Cost of illness and drivers of cost in atrial fibrillation in Sweden and Germany.

Jönsson L; Eliasson A; Kindblom J; Almgren O; Edvardsson N
Article: INFLAMMATORY BOWEL DISEASES. 2009;15(12):1882-1890

Resource Use and Societal Costs for Crohn's Disease in Sweden

Mesterton J; Jonsson L; Almer SHC; Befrits R; Friis-Liby I; Lindgren S
Article: INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2009;24(10):1072-1078

Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies

Gustavsson A; Van der Putt R; Jonsson L; McShane R
Journal article: JOURNAL OF NUTRITION HEALTH & AGING. 2009

IPECAD5 — Fifth International Pharmaco-Economic Conference on Alzheimer’s Disease

Gustavsson A; Jonsson L; Fillit H; Johansson G; Wimo A; Winblad B
Journal article: ALZHEIMERS & DEMENTIA. 2009;5(4S_Part_13):p410

P3‐228: Trends in informal care in Sweden: Is it decreasing? Cross‐sectional studies with the RUD instrument

Wimo A; Wimo A; Sjolund B; Jönsson L; Skoldunger A; Winblad B
Journal article: GERONTOLOGIE ET SOCIETE. 2009;vol. 32 / n° 128-129(1):297-318

Impact socio-économique de la maladie d'Alzheimer et des maladies apparentées en Europe

Kenigsberg P-A; Ersek K; Gulácsi L; Karpati K; Jacques A; Gustavsson A; Jönsson L; Mcdaid D; Valtonen H; Wimo A
Article: EUROPEAN RADIOLOGY. 2009;19:S753-S763

Health-economic evaluation of three imaging strategies in patients with suspected colorectal liver metastases: Gd-EOB-DTPA-enhanced MRI vs. extracellular contrast media-enhanced MRI and 3-phase MDCT in Germany, Italy and Sweden

Zech CJ; Grazioli L; Jonas E; Ekman M; Niebecker R; Gschwend S; Breuer J; Jonsson L; Kienbaum S
Article: LAKARTIDNINGEN. 2009;106(18-19):1277-1282

[Prevalence study of societal costs for dementia 2000-2005. More demented people--but somewhat reduced costs per person].

Wimo A; Johansson L; Jönsson L
Journal article: ALZHEIMERS & DEMENTIA. 2008;4(4S_Part_20):t661

P3‐476: Willingness to pay for reductions in care need: Estimating the value of informal care

Gustavsson A; Jönsson L; Zbrozek AS
Article: BMJ-BRITISH MEDICAL JOURNAL. 2008;336(7636):134-138

Community occupational therapy for older patients with dementia and their care givers:: cost effectiveness study

Graff MJL; Adang EMM; Vernooij-Dassen MJM; Dekker J; Jonsson L; Thijssen M; Hoefnagels WHL; Rikkert MGMO
Article: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2007;61(8):1410-1414

Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid-lowering drugs

Lindgren P; Borgstrom F; Stalhammar J; Alemao E; Jonsson L
Journal article: ALZHEIMERS & DEMENTIA. 2007;3(3S_Part_3):s165

S1–01–01: Public health impact

Winblad B; Wimo A; Jonsson L
Journal article: ALZHEIMERS & DEMENTIA. 2007;3(3S_Part_2):s146

P‐148: The resource utilization in dementia (RUD) instrument is valid to assess informal care time in dementia

Wimo A; Jönsson L; Zbrozek AS
Article: INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2007;22(7):649-655

Health utilities in mild cognitive impairment and dementia:: a population study in Sweden

Ekman M; Berg J; Wimo A; Jonsson L; McBurney C
Article: INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2007;22(7):639-648

Time use and costs of institutionalised elderly persons with or without dementia:: results from the Nordanstig cohort in the Kungsholmen Project -: a population based study in Sweden

Nordberg G; Wimo A; Jonsson L; Kareholt I; Sjolund B-M; Lagergren M; von Strauss E
Article: ALZHEIMER DISEASE & ASSOCIATED DISORDERS. 2007;21(2):150-154

Patients with dementia with lewy bodies have more impaired quality of life than patients with Alzheimer disease

Bostrom F; Jonsson L; Minthon L; Londos E
Article: ALZHEIMERS & DEMENTIA. 2007;3(2):81-91

An estimate of the total worldwide societal costs of dementia in 2005

Wimo A; Winblad B; Jonsson L
Article: BREAST CANCER RESEARCH AND TREATMENT. 2007;102(3):289-299

Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden

Lundkvist J; Wilking N; Holmberg S; Jonsson L
Article: NEUROEPIDEMIOLOGY. 2007;29(1-2):29-38

The ICTUS study:: A prospective longitudinal observational study of 1,380 AD patients in Europe -: Study design and baseline characteristics of the cohort

Reynish E; Cortes F; Andrieu S; Cantet C; Rikkert MO; Melis R; Froelich L; Frisoni GB; Joensson L; Visser PJ; Ousset PJ; Vellas B
Journal article: ALZHEIMERS & DEMENTIA. 2006;2(3S_Part_1):s19-s20

O1–05–08: The worldwide directs costs and costs of informal care of dementia

Winblad B; Wimo A; Jönsson L
Article: VALUE IN HEALTH. 2006;9(3):193-198

Cost of hypoglycemia in patients with type 2 diabetes in Sweden

Jönsson L; Bolinder B; Lundkvist J
Article: INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2006;21(5):449-459

Determinants of costs of care for patients with Alzheimer's disease

Jonsson L; Jonhagen ME; Kilander L; Soininen H; Hallikainen M; Waldemar G; Nygaard H; Andreasen N; Winblad B; Wimo A
Article: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2006;6(2):121-128

Lipid management and cholesterol goal attainment in Norway.

Ose L; Skjeldestad FE; Bakken IJ; Levorsen A; Alemao EA; Yin DD; Borgström F; Jönsson L
Article: ALZHEIMER DISEASE & ASSOCIATED DISORDERS. 2006;20(1):49-55

Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL

Jönsson L; Andreasen N; Kilander L; Soininen H; Waldemar G; Nygaard H; Winblad B; Jönhagen ME; Hallikainen M; Wimo A
Article: DEMENTIA AND GERIATRIC COGNITIVE DISORDERS. 2006;21(3):175-181

An estimate of the worldwide prevalence and direct costs of dementia in 2003

Wimo A; Jonsson L; Winblad B
Article: JOURNAL OF CARDIOVASCULAR RISK. 2005;12(6):530-534

Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice

Lindgren P; Borgström F; Stålhammar J; Alemao E; Yin DDP; Jönsson L
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2005;6(3):197-202

The economic and quality of life impact of hypoglycemia.

Lundkvist J; Berne C; Bolinder B; Jönsson L
Journal article: JOURNAL OF HUMAN HYPERTENSION. 2005;19(8):662

The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke:: results from the Study on COgnition and Prognosis in the Elderly (vol 19, pg 569, 2005)

Lundkvist J; Ekman M; Kartman B; Carlsson J; Jönsson L; Lithell H
Article: SPINE. 2005;30(15):1777-1785

Burden of illness of chronic low back pain in Sweden a cross-sectional, retrospective study in primary care setting

Ekman M; Jönhagen S; Hunsche E; Jönsson L
Journal article: ALZHEIMERS & DEMENTIA. 2005;1(1S_Part_3):s101

[O2‐04‐01]: The worldwide costs of dementia

Winblad B; Jönsson L; Wimo A
Article: JOURNAL OF HUMAN HYPERTENSION. 2005;19(7):569-576

The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke:: results from the Study on COgnition and Prognosis in the Elderly

Lundkvist J; Ekman M; Kartman B; Carlsson J; Jönsson L; Lithell H
Article: AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY. 2005;3(2):77-86

Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.

Jönsson L
Article: EUROPEAN JOURNAL OF NEUROLOGY. 2005;12:50-53

Cost of dementia in Europe

Jönsson L; Berr C
Article: ALLERGY. 2005;60(3):338-342

Association between allergic rhinitis and hospital resource use among asthmatic children in Norway

Kocevar VS; Thomas J; Jonsson L; Valovirta E; Kristensen F; Yin DD; Bisgaard H
Journal article: JOURNAL OF MEDICAL ECONOMICS. 2005;8(1-4):131-138

Cost-effective prevention of renal failure in type 2 diabetics using losartan

Jönsson L; Carides GW; Burke TA; Brandt A-SI; Salonen T; Schön S; Weiss L
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2004;5 Suppl 1:S30-S35

Economic evidence in dementia: a review.

Jönsson L
Article: RHEUMATOLOGY. 2004;43(9):1158-1166

The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade®)

Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J
Article: CHEST. 2004;125(5):1680-1684

Variations in pediatric asthma hospitalization rates and costs between and within Nordic countries

Kocevar VS; Bisgaard H; Jönsson L; Valovirta E; Kristensen F; Yin DD; Thomas J
Journal article: ATHEROSCLEROSIS PLUS. 2004;5(1):141

M.607 Current management of hyperlipidemia in Norway and factors associated with cholesterol goal attainment

Ose L; Skjeldestad F; Bakken I; Levorsen A; Alemao E; Yin D; Borgström F; Jönsson L
Article: PHARMACOECONOMICS. 2004;22:25-35

Cost of care for patients treated with lipid-lowering drugs

Carlsson Å; Borgström F; Stålhammar J; Alemao E; Yin D; Jönsson L
Article: UGESKRIFT FOR LAEGER. 2003;165(43):4112-4116

[Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial].

Jönsson L; Borgström F; Zethraeus N
Article: HERNIA. 2003;7(3):114-117

Cost analysis of incisional hernia repair by suture or mesh.

Israelsson LA; Jönsson L; Wimo A
Journal article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2003;4(1):50-59

Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis.

Kobelt G; Jönsson L; Fredrikson S
Article: RHEUMATOLOGY. 2003;42(2):326-335

The cost-effectiveness of infliximab (Remicade®) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study

Kobelt G; Jönsson L; Young A; Eberhardt K
Article: PHARMACOECONOMICS. 2003;21(5):305-314

Cost effectiveness of alendronate (Fosamax®) for the treatment of osteoporosis and prevention of fractures

Johnell O; Jönsson B; Jönsson L; Black D
Article: ARTHRITIS & RHEUMATOLOGY. 2002;46(9):2310-2319

Modeling the progression of rheumatoid arthritis -: A two-country model to estimate costs and consequences of rheumatoid arthritis

Kobelt G; Jönsson L; Lindgren P; Young A; Eberhardt K
Article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2002;18(1):127-138

Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data

Kobelt G; Jönsson L; Miltenburger C
Article: BLOOD PRESSURE. 2002;11(1):46-52

The potential economic consequences of cognitive improvement with losartan

Jönsson L; Gerth W; Fastbom J
Article: LAKARTIDNINGEN. 2001;98(38):4042-4048

Can the cost of future health care and social services needs of the elderly be calculated?

Wimo A; Jönsson L
Article: DERMATOLOGY. 2001;202(1):38-43

Pharmacoeconomic evaluation of calcipotriol (Daivonex®/Dovonex®) and UVB phototherapy in the treatment of psoriasis:: A Markov model for the Netherlands

de Rie MA; de Hoop D; Jönsson L; Bakkers EJM; Sorensen M
Journal article: VALUE IN HEALTH. 2000;3(5):376

PHDE4: PHARMACOECONOMIC EVALUATION OF CALCIPOTRIOL AND UVB IN THE TREATMENT OF PSORIASIS IN THE NETHERLANDS

de Rie M; de Hoop D; Jonsson L; Bakkers E; Sorensen M
Article: ALZHEIMER DISEASE & ASSOCIATED DISORDERS. 2000;14(3):137-140

Second International Pharmacoeconomic Conference on Alzheimer's Disease

Jönsson L; Jönsson B; Wimo K; Whitehouse P; Winblad B
Article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2000;16(3):768-780

Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis

Kobelt G; Jönsson L; Henriksson F; Fredrikson S; Jönsson B
Article: PHARMACOECONOMICS. 1999;16(4):409-416

Costs of mini mental state examination-related cognitive impairment

Jönsson L; Lindgren P; Wimo A; Jönsson B; Winblad B
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 1999;9:289

A cost-effectiveness clinical decision analysis for schizophrenia: Results from Sweden

Wieselgren I-M; Lindström E; Lindström L; Jönsson L
Article: CLINICAL THERAPEUTICS. 1999;21(7):1230-1240

The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease:: A Markov model

Jönsson L; Lindgren P; Wimo A; Jönsson B; Winblad B
Article: ARTHRITIS & RHEUMATOLOGY. 1999;42(2):347-356

Economic consequences of the progression of rheumatoid arthritis in Sweden

Kobelt G; Eberhardt K; Jönsson L; Jönsson B
Article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 1999;15(1):207-219

Modeling cost of treatment with new topical treatments for glaucoma -: Results from France and the United Kingdom

Kobelt G; Jönsson L
Article: GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY. 1998;236(11):811-821

Direct costs of glaucoma management following initiation of medical therapy - A simulation model based on an observational study of glaucoma treatment in Germany

Kobelt G; Jonsson L; Gerdtham U; Krieglstein GK
Article: NEUROUROLOGY AND URODYNAMICS. 1998;17(6):599-611

Cost-effectiveness of new treatments for overactive bladder: The example of tolterodine, a new muscarinic agent: A Markov model

Kobelt G; Jonsson L; Mattiasson A
Show more

All other publications

Review: ALZHEIMERS & DEMENTIA. 2024;20(6):4290-4314

The 2022 symposium on dementia and brain aging in low- and middle-income countries: Highlights on research, diagnosis, care, and impact

Kalaria R; Maestre G; Mahinrad S; Acosta DM; Akinyemi RO; Alladi S; Allegri RF; Arshad F; Babalola DO; Baiyewu O; Bak TH; Bellaj T; Brodie-Mends DK; Carrillo MC; Celestin K-K; Damasceno A; de Silva RK; de Silva R; Djibuti M; Dreyer AJ; Ellajosyula R; Farombi TH; Friedland RP; Garza N; Gbessemehlan A; Georgiou EE-Z; Govia I; Grinberg LT; Guerchet M; Gugssa SA; Gumikiriza-Onoria JL; Hogervorst E; Hornberger M; Ibanez A; Ihara M; Issac TG; Joensson L; Karanja WM; Lee JH; Leroi I; Livingston G; Manes FF; Mbakile-Mahlanza L; Miller BL; Musyimi CW; Mutiso VN; Nakasujja N; Ndetei DM; Nightingale S; Novotni G; Nyamayaro P; Nyame S; Ogeng'o JA; Ogunniyi A; de Oliveira MO; Okubadejo NU; Orrell M; Paddick S-M; Pericak-Vance MA; Pirtosek Z; Potocnik FCV; Raman R; Rizig M; Rosselli M; Salokhiddinov M; Satizabal CL; Sepulveda-Falla D; Seshadri S; Sexton CE; Skoog I; George-Hyslop PHS; Suemoto CK; Thapa P; Udeh-Momoh CT; Valcour V; Vance JM; Varghese M; Vera JH; Walker RW; Zetterberg H; Zewde YZ; Ismail O
Review: JOURNAL OF INTERNAL MEDICINE. 2024;295(3):281-291

People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare

Wahlberg K; Winblad B; Cole A; Herring WL; Ramsberg J; Torontali I; Visser P-J; Wimo A; Wollaert L; Jonsson L
Preprint: MEDRXIV. 2024

Generate Synthetic Data in R for a Hypothetical Alzheimer’s Disease Trial

Handels R; Jönsson L; Raket LL; Initiative TADN
Conference publication: VALUE IN HEALTH. 2023;26(12):s1

P3 Open-Source Model Framework for Health-Economic Evaluation of Early Treatment in Alzheimer's Disease

Handels R; Wimo A; Skoldunger A; Tate A; Winblad B; Silvertand D; Nguyen L; Jönsson L; Grimm S; Aye S; Herring W
Conference publication: ANNALS OF ONCOLOGY. 2023;34:s833-s834

Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis

Kim K; Sweeting M; Wilking N; Jonsson L
Letter: ALZHEIMERS & DEMENTIA. 2023;19(10):4760-4763

Response to "Comment on 'Dementia prevention: The potential long-term cost-effectiveness of the FINGER prevention program'"

Wimo A; Handels R; Antikainen R; Eriksdotter M; Jonsson L; Knapp M; Kulmala J; Laatikainen T; Lehtisalo J; Peltonen M; Skoldunger A; Soininen H; Solomon A; Strandberg T T; Tuomilehto J; Ngandu T; Kivipelto M
Conference publication: NEUROLOGY. 2023;100(17)

Patient-identified most bothersome symptom as a driver of health-related quality of life experienced by patients with migraine

Jonsson L; Awad SF; Regnier SA; Talon B; Kymes S; Lee XY; Goadsby PJ
Conference publication: NEUROLOGY. 2023;100(17)

Effect of Eptinezumab on Utility Scores in Patients with Migraine: Results from the DELIVER Study

Jonsson L; Regnier SA; Kymes S; Talon B; Awad SF; Lee XY; Goadsby PJ
Editorial comment: ALZHEIMERS & DEMENTIA. 2023;19(3):1105-1108

The Nairobi Declaration-Reducing the burden of dementia in low- and middle-income countries (LMICs): Declaration of the 2022 Symposium on Dementia and Brain Aging in LMICs

Maestre G; Carrillo M; Kalaria R; Acosta D; Adams L; Adoukonou T; Akinwande K; Akinyemi J; Akinyemi R; Akpa O; Alladi S; Allegri R; Arizaga R; Arshad F; Arulogun O; Ndetei D; Baiyewu O; Issac T; Bellaj T; Boshe J; Brayne C; Brodie-Mends D; Brown R; Cahn J; Cyrille N; Damasceno A; de Silva R; de Silva R; Djibuti M; Dreyer AJ; Ellajosyula R; Farombi T; Fongang B; Forner S; Friedland R; Garza N; Gbessemehlan A; Georgiou EE-Z; Gouider R; Govia I; Grinberg L; Guerchet M; Gugssa S; Gumikiriza-Onoria JL; Gustafson D; Hogervorst E; Hornberger M; Ibanez A; Ihara M; Ismail O; Issac T; Joensson L; Kaputu C; Karanja W; Karungi J; Tshala-Katumbay D; Kunkle B; Lee JH; Leroi I; Lewis R; Livingston G; Lopera F; Lwere K; Manes F; Mbakile-Mahlanza L; Mena P; Miller B; Millogo A; Mohamed A; Musyimi C; Mutiso V; Nakasujja N; Ndetei D; Nightingale S; Njamnshi AK; Novotni G; Nyamayaro P; Nyame S; Ogeng'o J; Ogunniyi A; De Oliveira MO; Okubadejo N; Orrell M; Orunmuyi A; Owolabi M; Paddick S; Pericak-Vance MA; Pirtosek Z; Potocnik F; Preston B; Raman R; Ranchod K; Rizig M; Rosselli M; Deepa R; Roy U; Salokhiddinov M; Sano M; Sarfo F; Satizabal CL; Sepulveda-Falla D; Seshadri S; Sexton C; Skoog I; St George-Hyslop P; Suemoto C; Tanner J; Thapa P; Toure K; Ucheagwu V; Udeh-Momoh C; Valcour V; Vance J; Varghese M; Vera J; Walker R; Weidner W; Sebastian W; Gay PW; Zetterberg H; Zewde Y
Preprint: MEDRXIV. 2023

Potential cost-effectiveness of individualized medicine in prodromal Alzheimer’s disease by demographic, clinical and cerebrospinal fluid proteomics factors

Handels R; Wesenhagen K; Tijms B; Teunissen C; Visser PJ; Jönsson L
Review: PHARMACOECONOMICS. 2023;41(1):59-75

The Costs of Dementia in Europe: An Updated Review and Meta-analysis

Jonsson L; Tate A; Frisell O; Wimo A
Editorial comment: JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE. 2023;10(3):349-352

Amyloid-targeting New Therapies for Alzheimer's Disease: A Health Economics Perspective

Jonsson L; Wimo A
Editorial comment: LANCET REGIONAL HEALTH-EUROPE. 2022;20:100472

The personal economic burden of dementia in Europe Comment

Jonsson L
Conference publication: VALUE IN HEALTH. 2022;25(12):S390

DISEASE-SPECIFIC QUALITY-OF-LIFE MEASURES MAPPED TO THE EQ-5D IN A CHRONIC DISORDER WITH RECURRENT ATTACKS: ANALYSIS OF THE DELIVER TRIAL IN PATIENTS WITH MIGRAINE

Jonsson L; Regnier SA; Kymes S; Awad SF; Talon B; Lee XY; Goadsby PJ
Conference publication: VALUE IN HEALTH. 2022;25(12):S436

EFFECT OF EPTINEZUMAB ON UTILITY SCORES IN PATIENTS WITH MIGRAINE: RESULTS FROM THE DELIVER STUDY

Jonsson L; Regnier SA; Kymes S; Talon B; Awad SF; Lee XY; Goadsby PJ
Conference publication: VALUE IN HEALTH. 2022;25(12):S483

EFFECT OF MORTALITY ON COST-EFFECTIVENESS MODELING OF DISEASE-MODIFYING TREATMENT FOR ALZHEIMER'S DISEASE

Aye S; Jonsson L
Conference publication: VALUE IN HEALTH. 2022;25(12):S31-S32

PREDICTING SOJOURN TIMES BY DEMENTIA STAGES: EVIDENCE FROM 76,747 PATIENTS IN THE SWEDISH NATIONAL REGISTRY FOR COGNITIVE DISORDERS (SVEDEM)

Tate A; Jonsson L
Preprint: RESEARCH SQUARE. 2020

Prognosis of Alzheimer’s disease; what do patients and care partners want to know?

Mank A; Maurik IV; Bakker E; Glind EMMVD; Jönsson L; Kramberger M; Novak P; Diaz A; Gove D; Scheltens P; Flier WVD; Visser LNC
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2019;28:302

How different regulatory systems recognize and reward pharmaceutical innovation - a comparative analysis of intelectual property (IP) protection, marketing authorization and pricing/reimbursement systems with a focus on oncology

Justo N; Jonsson L; Wilking N
Conference publication: EUROPEAN JOURNAL OF NEUROLOGY. 2019;26:745-746

Costs of stroke rehabilitation in patients with dementia: a Swedish register-based study

Hoang MT; Kareholt I; Von Euler M; Jonsson L; Von Koch L; Eriksdotter M; Garcia-Ptacek S
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2018;24:571

Real-world outcome in multiple sclerosis estimated from two cost of illness studies and MS clinic data in the Czech Republic

Kobelt G; Jonsson L; Pavelkova M; Kubala EH
Editorial comment: ALZHEIMERS & DEMENTIA. 2017;13(3):201-204

Special topic section on health economics and public policy of Alzheimer's disease

Jonsson L; Lin P-J; Khachaturian AS
Corrigendum: ALZHEIMERS RESEARCH & THERAPY. 2017;9(1):12

The societal costs of dementia in Sweden 2012 - relevance and methodological challenges in valuing informal care (vol 8, 59, 2016)

Wimo A; Jonsson L; Fratiglioni L; Sandman PO; Gustavsson A; Skoldunger A; Johansson JL
Conference publication: VALUE IN HEALTH. 2016;19(7):A524

ESTIMATING THE ECONOMIC BURDEN ASSOCIATED WITH THE EARLY STAGES OF PROGRESSION OF ALZHEIMER'S DISEASE IN EUROPE

Lindgren P; Jonsson L; Coste F; Chan E; Bosshard R
Conference publication: VALUE IN HEALTH. 2013;16(7):a611

STRUCTURAL FAILURE TIME MODELING OF OVERALL SURVIVAL EFFECTS IN ONCOLOGY TRIALS WITH SUBSEQUENT THERAPIES

Jonsson L; Fleischer F; Bluhmki E; Griebsch I
Conference publication: VALUE IN HEALTH. 2013;16(7):a610

EVALUATING OVERALL SURVIVAL IN ONCOLOGY TRIALS WITH SUBSEQUENT THERAPIES: A METHODOLOGICAL REVIEW AND APPLICATION IN NON-SMALL CELL LUNG CANCER

Jonsson L; Fleischer F; Bluhmki E; Griebsch I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2013;72:477-478

COSTS AND WORKING CAPACITY AMONG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN WORKING-AGE (18-64 YEARS)

Bexelius C; Wachtmeister K; Skare P; Jonsson L; van Vollenhoven RF
Conference publication: VALUE IN HEALTH. 2012;15(7):a317

PROPOSED AND ACTUAL BUREAUCRATIC BURDEN OF HTA SUBMISSIONS TO THE INDUSTRY-CASE STUDIES FROM GERMANY AND UK

Schweikert B; Jonsson L
Corrigendum: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2012;22(3):237-238

Cost of disorders of the brain in Europe 2010 (vol 21, pg 718, 2011)

Gustavsson A; Svensson M; Jacobi F; Allgulander C; Alonso J; Beghi E; Dodel R; Ekman M; Faravelli C; Fratiglioni L; Gannon B; Jones DH; Jennum P; Jordanova A; Jonsson L; Karampampa K; Knapp M; Kobelt G; Kurth T; Lieb R; Linde M; Ljungcrantz C; Maercker A; Melin B; Moscarelli M; Musayev A; Norwood F; Preisig M; Pugliatti M; Rehm J; Salvador-Carulla L; Schlehofer B; Simon R; Steinhausen H-C; Stovner LJ; Vallat J-M; Van den Bergh P; van Os J; Vos PE; Xu W; Wittchen H-U; Jonsson B; Olesen J
Conference publication: VALUE IN HEALTH. 2012;15(7):A464

METHODS FOR ANALYSIS OF CENSORED COST DATA

Jonsson L
Conference publication: VALUE IN HEALTH. 2012;15(7):A422

SURVIVAL AND COSTS IN METASTATIC RENAL CELL CARCINOMA: A COMPARISON OF MRCC TREATMENT PRE- AND POST TYROSINE KINASE INHIBITOR (TKI) INTRODUCTION USING RETROSPECTIVE REGISTRY DATA

Jonsson L; Sandin R; Lindgren P; Kowalski J; Wahlgren T; Harmenberg U; Sandstrom P; Ljungberg B; Jakobsson M
Conference publication: VALUE IN HEALTH. 2011;14(7):A289

MORTALITY IN RELATION TO DISEASE SEVERITY IN SUBJECTS WITH DEMENTIA

Jonsson L; Fratiglioni L; Wimo A
Conference publication: EUROPEAN JOURNAL OF CANCER. 2011;47:s663

Chemotherapy Treatment Patterns in Patients With Metastatic Soft Tissue Sarcoma - the Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study

Leahy M; del Muro X; Pisters P; Reichardt P; Jonsson L; Eriksson J; Baffoe-Bonnie A; Burke T; Blay JY
Meeting abstract: VALUE IN HEALTH. 2010;13(7):a282

EXTRAPOLATION IN TRIAL-BASED COST-EFFECTIVENESS MODELING: IN SEARCH OF A STANDARD

Ekman M; Charbonneau C; Ramsberg J; Jonsson L; Sandin R; Jonsson B; Drummond M; Weinstein MC
Meeting abstract: VALUE IN HEALTH. 2010;13(7):a246

ANALYZING OVERALL SURVIVAL IN RANDOMIZED CONTROLLED TRIALS WITH CROSS-OVER

Jonsson L; Sandin R; Ekman M; Ramsberg J; Charbonneau C; Huang X; Jonsson B; Weinstein MC; Drummond M
Conference publication: ANNALS OF ONCOLOGY. 2010;21:414-415

HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH METASTATIC SARCOMA - THE SARCOMA TREATMENT AND BURDEN OF ILLNESS STUDY IN NORTH AMERICA AND EUROPE (SABINE) STUDY

Leahy M; Reichardt P; Del Muro XG; Pisters P; Chawla S; Martin J; Jonsson L; Eriksson J; Burke T; Blay J-Y
Conference publication: EUROPEAN JOURNAL OF NEUROLOGY. 2010;17:75

Age affects quality and cost of dementia diagnosis

Religa D; Spangberg K; Wimo A; Jonsson L; Edlund A-K; Winblad B; Jonhagen ME
Conference publication: VALUE IN HEALTH. 2009;12(7):a369

COST-EFFECTIVENESS OF DONEPEZIL IN ALZHEIMER'S DISEASE IN SWEDEN

Mesterton J; By A; Sandelin R; Jonsson L
Conference publication: VALUE IN HEALTH. 2009;12(7):a361

A PATIENT PERSPECTIVE ON SIDE EFFECTS OF ANTIPSYCHOTIC THERAPY: THE TOOL INSTRUMENT

Lindstrom E; Jonsson L; Berntsson A
Conference publication: VALUE IN HEALTH. 2009;12(7):a361-a362

TOOL: MULTI-ATTRIBUTE UTILITY FUNCTION REFLECTING PATIENT EXPERIENCE OF SIDE EFFECTS TO ANTIPSYCHOTIC THERAPY

Jonsson L; Lang A; Lindstrom E
Meeting abstract: VALUE IN HEALTH. 2009;12(3):a176

ECONOMIC EVALUATION OF AGOMELATINE FOR MAJOR DEPRESSIVE DISORDER IN SWEDEN

Clapham E; Berg J; Ekman M; Jonsson L
Review: JOURNAL OF ALZHEIMERS DISEASE. 2009;16(2):235-270

Methodological Issues in Primary Prevention Trials for Neurodegenerative Dementia

Andrieu S; Coley N; Aisen P; Carrillo MC; DeKosky S; Durga J; Fillit H; Frisoni GB; Froelich L; Gauthier S; Jones R; Jonsson L; Khachaturian Z; Morris JC; Orgogozo J-M; Ousset P-J; Robert P; Salmon E; Sampaio C; Verhey F; Wilcock G; Vellas B
Conference publication: JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS. 2009;12:S28

Adherence to Initial Antidepressant Therapy is Associated with Lower Resource Use and Higher Health Utility in a Longitudinal Survey of Patients with Depression in Sweden

Marteau F; Despiegel N; Jonsson L
Preprint: SSRN ELECTRONIC JOURNAL. 2009

Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective?

Johannesson M; Jonsson B; Jonsson L; Kobelt G; Zethraeus N
Conference publication: EUROPEAN JOURNAL OF NEUROLOGY. 2009;16:358

The lower cost of dementia diagnosis in women

Religa D; Spangberg K; Wimo A; Jonsson L; Edlund A-K; Johansson N; Winblad B; Eriksdotter MJ
Review: PHARMACOECONOMICS. 2009;27(5):391-403

The Cost of Dementia in Europe A Review of the Evidence, and Methodological Considerations

Jonsson L; Wimo A
Meeting abstract: VALUE IN HEALTH. 2008;11(6):a423-a424

COST OF INSOMNIA IN PATIENTS OVER 54YEARS IN SWEDEN

Justo N; Jonsson L; Ekman M; Berg J
Conference publication: VALUE IN HEALTH. 2007;10(6):a387

Mild to moderate Alzheimer's disease associated with significanttime burden to caregivers

Jonsson L; Grundman M; Black R; Liu E; Minassian S; Zbrozek A; Leibman C; Lucas C; McLaughlin T
Review: INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2007;22(8):713-719

Patients with Lewy body dementia use more resources than those with Alzheimer's disease

Bostrom F; Jonsson L; Minthon L; Londos E
Published conference paper: JOURNAL OF NUTRITION HEALTH & AGING. 2007;11(4):353-355

Assessing health economic outcome in Alzheimer's disease clinical trials

Jonsson L
Conference publication: VALUE IN HEALTH. 2007;10(3):A82

Disease progression in Alzheimer's disease patients treated with a cholinesterase inhibitor in clinical practice

Gustavsson A; Parmler J; Ganguly R; Minthon L; Jonsson L
Meeting abstract: VALUE IN HEALTH. 2007;10(3):a83

A multi-domain micro-simulation economic modeling framework in Alzheimer's disease

Jonsson L; Gustavsson A; Ganguly R
Conference publication: EUROPEAN HEART JOURNAL. 2007;28:260

Atrial fibrillation-costs and determinants of costs of illness in two European countries

Ericsson A; Jonsson L; Kindblom J; Almgren O; Edvardsson N
Conference publication: VALUE IN HEALTH. 2006;9(6):a346

Cost-effectiveness of rosuvastatin for cardiovascular prevention in high-risk populations in Sweden

Jonsson L; Ekman M; Karlsson G; Brun J
Corrigendum: ALZHEIMER DISEASE & ASSOCIATED DISORDERS. 2006;20(2):125

Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. (vol 20, pg 49, 2006)

Jonsson L; Andreasen N; Kilander L; Soininen H; Waldemar G; Nygaard H; Winblad B; Eriksdotter JM; Hallikainen M; Wimo A
Conference publication: EUROPEAN JOURNAL OF NEUROLOGY. 2005;12:8

European Brain Council:: Epidemiology of brain diseases in Europe

Dodel R; Andlin-Sobocki P; Beghi E; Berg J; Jonsson L; Ekman M; Forsgren L; Jonsson B; Kobelt G; Lindgren P; Olesen J; Westphal M; Wittchen HU
Conference publication: NEUROBIOLOGY OF AGING. 2004;25:s481

Costs of formal dementia care in Europe

Zbrozek AS; Brandt AS; Jönsson L
Conference publication: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2004;43(5):a464-464A

Cholesterol goal attainment is associated with lower incidence of cardiovascular events and cost of care

Jönsson L; Borgström F; Stålhammar J; Alemao E; Yin DDP
Conference publication: JOURNAL OF NEUROLOGY. 2004;251:44

Interferon beta-1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis:: results of a Markov disease model for Sweden and the UK

Kobelt G; Jönsson L; Fredrikson S
Conference publication: EUROPEAN HEART JOURNAL. 2003;24:246

Cost-effectiveness of ezetimibe co-administration in coronary artery disease patients not at goal with current statin therapy in Sweden

Cook JR; Jönsson L; Yin D; Alemao E; Huse D; Drummond M
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2003;48(9):S658

The burden of AS and the cost-effectiveness of treatment.

Kobelt G; Andlin-Sobocki P; Jönsson L; Brophy S; Calin A; Braun J
Conference publication: INTERNATIONAL PSYCHOGERIATRICS. 2003;15:156-157

Cost of care and quality of life in patients with Alzheimer's disease in relation to comorbidities:: Results from a Nordic study

Jönsson L; Eriksdotter-Jönhagen M; Kilander L; Soininen H; Waldemar G; Nygaard H
Review: PHARMACOECONOMICS. 2003;21(14):1025-1037

Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease

Jönsson L
Book chapter: DEMENTIA. 2002;p. 341-387

Costs of Dementia: A Review

Jönsson B; Jönsson L; Wimo A
Conference publication: OSTEOPOROSIS INTERNATIONAL. 2002;13:S45

Cost-effectiveness of alendronate for the treatment of male osteoprosis in Sweden

Borgström F; Sen SS; Johnell O; Jönsson B; Jönsson L; Zethreaus N
Conference publication: NEUROBIOLOGY OF AGING. 2002;23(1):S48

Costs of care and health-related quality of life in patients with Alzheimer's disease and their caregivers

Jönsson L; Jönhagen ME; Winblad B; Kilander L; Soininen H; Waldemar G; Nygaard H
Scholarly edition: 2001

Cost-utility analysis of Interferon Beta-1b in the treatment of different types of Multiple Sclerosis

Kobelt G; Jönsson L; Fredriksson S; Jönsson B
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2001;44(9):S158

Cost-effectiveness of infliximab (Remicade) in Sweden

Kobelt G; Jonsson L; Lindquist E; Eberhardt K
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2001;44(9):S312

Economic consequences of the progression of rheumatoid arthritis in Sweden and the United Kingdom.

Kobelt G; Jonsson L; Lindgren P; Eberhardt K; Young A
Book chapter: DEMENTIA. 2000;p. 335-381

Costs of Dementia: A Review

Jönsson B; Jönsson L; Wimo A
Conference publication: OSTEOPOROSIS INTERNATIONAL. 2000;11:S9

Cost-effectiveness of Fosamax® (alendronate) for the treatment of osteoporosis and prevention of fractures

Johnell O; Jönsson B; Jönsson L; Black D
Conference publication: JOURNAL OF UROLOGY. 1998;159(5):302

Cost-effectiveness of tolterodine, a new treatment for symptoms of overactive bladder.

Kobelt G; Jonsson L; Lund AM
Show more

Grants

FINGER-Pro: Evidence-based health promotion interventions for healthy aging: adapting and implementing the FINGER multidomain model across different settings and sociocultural contexts

Swedish Research Council for Health Working Life and Welfare

1 October 2023 - 30 September 2029
PREDEM: precision diagnostics and treatment och cognitive disorders and prevention of dementia

VINNOVA

1 October 2021 - 30 September 2026
Alzheimer’s disease data-driven insights on individual outcomes of importance

Swedish Research Council for Health Working Life and Welfare

1 January 2019 - 31 December 2021

Employments

Professor, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 2023-

Degrees and Education

Docent, Karolinska Institutet, 2019
Doctor Of Philosophy, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 2003

About me

Articles

All other publications

Grants

Employments

Degrees and Education

News from KI

Events from KI